Inventia Life Science launches RASTRUM Validated Solutions to accelerate decision-grade data

16 April 2026

Sydney, Australia-based Inventia Life Science announces the launch of RASTRUM™ Validated Solutions, a new product offering designed to help drug discovery teams generate decision-grade data from human-relevant 3D cell models with greater speed, confidence, and reproducibility.

Through its RASTRUM bioprinting platform, workflow-driven software, and scientific expertise, Inventia Life Science supports researchers with biologically relevant in vitro models at scale for disease modeling, mechanistic biology, and drug discovery.

Inventia's RASTRUM™ Validated Solutions are pre‑validated, ready‑to‑run 3D disease‑model workflows that apply to the RASTRUM bioprinter and its reagents.  Each Validated Solution

provides a fully defined protocol (Protocol Pack) and accompanying validation dataset (Data Pack), allowing users to bioprint a human‑relevant 3D model that has already been optimized and biologically confirmed by Inventia. This lets drug‑discovery teams bypass model development and immediately generate reproducible, decision‑grade data.

The first RASTRUM Validated Solutions released today are built for pancreatic ductal adenocarcinoma (PDAC) and fibroblast activation. The PDAC model blueprint facilitates reproducible drug response studies in the context of tumor-stromal interactions. The Fibroblast Activation model blueprint supports controlled modeling of lung fibroblast activation and signaling, with applications for understanding these processes in the tumor microenvironment and in fibrotic disease initiation.

“RASTRUM Validated Solutions are about helping drug discovery teams get to decision-grade data faster,” said Cameron Ferris, PhD, Co-Founder and COO, Inventia Life Science. “RASTRUM Allegro already gives teams the speed and reproducibility needed for scalable 3D workflows. With Validated Solutions, we are building on that foundation with predefined model blueprints, built for a defined context of use, that will help teams adopt human-relevant 3D biology quickly and use it for stronger decisions. This is an important step in supporting the real-world implementation of NAMs in discovery workflows.”

“From a scientific perspective, Validated Solutions bring structure to what matters most: model design, biological confirmation, functional readouts, and expected performance in a specific use case,” said Sean Porazinski, PhD, Head of Scientific Programs, Inventia Life Science. “Scientists get a validated model blueprint that is already grounded in reproducible 3D biology, with deep molecular and functional analysis to give confidence in generating human-relevant insights.”

For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.

Explore Access